CN104411321A - 用于口服施用的加载有多肽的聚(辛基氰基丙烯酸酯)纳米颗粒 - Google Patents

用于口服施用的加载有多肽的聚(辛基氰基丙烯酸酯)纳米颗粒 Download PDF

Info

Publication number
CN104411321A
CN104411321A CN201380031679.4A CN201380031679A CN104411321A CN 104411321 A CN104411321 A CN 104411321A CN 201380031679 A CN201380031679 A CN 201380031679A CN 104411321 A CN104411321 A CN 104411321A
Authority
CN
China
Prior art keywords
nano
particle
nanoparticles
peptide
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380031679.4A
Other languages
English (en)
Chinese (zh)
Inventor
S.M.克利夫兰
M.A.波利克
S.萨洛蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN104411321A publication Critical patent/CN104411321A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380031679.4A 2012-05-16 2013-05-16 用于口服施用的加载有多肽的聚(辛基氰基丙烯酸酯)纳米颗粒 Pending CN104411321A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
US61/647,633 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
CN104411321A true CN104411321A (zh) 2015-03-11

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380031679.4A Pending CN104411321A (zh) 2012-05-16 2013-05-16 用于口服施用的加载有多肽的聚(辛基氰基丙烯酸酯)纳米颗粒

Country Status (10)

Country Link
US (1) US20150342897A1 (https=)
EP (1) EP2849775A1 (https=)
JP (1) JP2015523332A (https=)
KR (1) KR20150010953A (https=)
CN (1) CN104411321A (https=)
AU (1) AU2013261214A1 (https=)
CA (1) CA2873536A1 (https=)
IN (1) IN2014DN09297A (https=)
RU (1) RU2014150850A (https=)
WO (1) WO2013171570A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109675020A (zh) * 2019-01-11 2019-04-26 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (zh) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 改善代谢综合症的功能服及其制造方法
CN105342999A (zh) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 艾塞那肽口服纳米粒
MX2023006163A (es) 2020-12-18 2023-06-08 Spectrum Brands Inc Herramienta de cepillado para animales y metodos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031231A1 (en) * 1995-04-04 1996-10-10 Elan Corporation, Plc Controlled release biodegradable nanoparticles containing insulin
CN101065116A (zh) * 2004-04-15 2007-10-31 安米林药品公司 包含多肽和糖的基于丙交酯/乙交酯共聚物的缓释微胶囊
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
EP1054594B1 (en) 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
BR122019021416A2 (https=) 2003-09-19 2019-12-21
CN102016814B (zh) 2005-06-17 2013-10-23 北卡罗来纳大学查珀尔希尔分校 纳米粒子制备方法、系统及材料
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031231A1 (en) * 1995-04-04 1996-10-10 Elan Corporation, Plc Controlled release biodegradable nanoparticles containing insulin
CN101065116A (zh) * 2004-04-15 2007-10-31 安米林药品公司 包含多肽和糖的基于丙交酯/乙交酯共聚物的缓释微胶囊
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAMGE C ET AL: "New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier", 《DIABETES》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109675020A (zh) * 2019-01-11 2019-04-26 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用

Also Published As

Publication number Publication date
KR20150010953A (ko) 2015-01-29
WO2013171570A1 (en) 2013-11-21
CA2873536A1 (en) 2013-11-21
US20150342897A1 (en) 2015-12-03
RU2014150850A (ru) 2016-07-10
AU2013261214A1 (en) 2014-11-20
JP2015523332A (ja) 2015-08-13
EP2849775A1 (en) 2015-03-25
IN2014DN09297A (https=) 2015-07-10

Similar Documents

Publication Publication Date Title
Verma et al. Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability
Cao et al. Nanocarriers for oral delivery of biologics: small carriers for big payloads
Gedawy et al. Oral insulin delivery: existing barriers and current counter-strategies
Asal et al. Controlled synthesis of in-situ gold nanoparticles onto chitosan functionalized PLGA nanoparticles for oral insulin delivery
Chalasani et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin
Song et al. Synthesis of CSK-DEX-PLGA nanoparticles for the oral delivery of exenatide to improve its mucus penetration and intestinal absorption
Wong et al. The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation
Chen et al. Long-acting release formulation of exendin-4 based on biomimetic mineralization for type 2 diabetes therapy
Shaji et al. Protein and peptide drug delivery: oral approaches
Soudry-Kochavi et al. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach
Hinds et al. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis
Ahn et al. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan
Seo et al. Sustained release of exendin 4 using injectable and ionic-nano-complex forming polymer hydrogel system for long-term treatment of type 2 diabetes mellitus
Damgé et al. Poly (ε-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes
Shrestha et al. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model
CN102908627B (zh) 用于口服胰岛素递送的pH敏感性纳米粒子
EP3099293B1 (en) Nanoencapsulation of hydrophilic active compounds
Alfatama et al. A comprehensive review of oral chitosan drug delivery systems: Applications for oral insulin delivery
Kanugo et al. New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics
CN110662550A (zh) 生理活性物质的口服给药
CN104411321A (zh) 用于口服施用的加载有多肽的聚(辛基氰基丙烯酸酯)纳米颗粒
US20100143484A1 (en) Oral submicron particle delivery system for proteins and process for its production
Pinto et al. Bioengineered nanomedicines targeting the intestinal fc receptor achieve the improved glucoregulatory effect of semaglutide in a type 2 diabetic mice model
Bouttefeux et al. Delivery of peptides via the oral route: diabetes treatment by peptide-loaded nanoparticles
Lu et al. Net-neutral nanoparticles-extruded microcapsules for oral delivery of insulin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150311